Spotlight
The Oncologist
Metastatic Site is a Key Prognostic Factor in Pancreatic Cancer
A new, Perthera, peer-reviewed study published in The Oncologist underscores the need to incorporate the metastatic site and genomic context in pancreatic cancer trial design.
Read more…
The Lancet Oncology
Patients with pancreatic cancer that receive matched therapies following molecular profiling survive longer
A peer-reviewed study published in The Lancet Oncology shows that patients experience up to a 2.4-fold improvement in progression-free survival when their provider follows Perthera Report ranked options.
Featured Content
Journal of Clinical Oncology
World’s First AI-Driven Chemo Predictor for Frontline Pancreatic Cancer Treatment
British Journal of Cancer
Multi-omic Testing’s Role in Improving Outcomes for Metastatic Breast Cancer
Highlighted Content
American Journal of Clinical Pathology
Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
Journal of Clinical Oncology
Real-World Use of PARP inhibitors in
BRCA-Mutated Pancreatic Cancer:
A Retrospective Analysis
AVAILABLE NOW: The Pethera Report® Pancreatic version | New Customers: Order your first report